CXCR6 and cancer: The generation of activated CXCR6+ NK cells in the peripheral blood that co‐express CD49a and adopt an “adaptive” phenotype, may allow hyperfunctional NK cells to be preferentially recruited to the liver, boosting the hepatic innate immune response to fight viruses and cancer, providing a basis for novel, locally acting immunotherapies for common hepatic disease.